A phase 3b M/C [multicentre], randomised, D/B [double-blind], P/G [parallel group], P/C [placebo controlled] study of omalizumab for the treatment of 12-75 year old patients with co-morbid moderate to severe allergic asthma and perennial allergic rhinitis

Trial Profile

A phase 3b M/C [multicentre], randomised, D/B [double-blind], P/G [parallel group], P/C [placebo controlled] study of omalizumab for the treatment of 12-75 year old patients with co-morbid moderate to severe allergic asthma and perennial allergic rhinitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 25 Jul 2005

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Asthma; Perennial allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jul 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top